The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Xerostomia (Dry Mouth Disease) Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global Xerostomia (Dry Mouth Disease) Therapeutics market size is expected to reach US$ 673.7 million by 2029, growing at a CAGR of 2.4% from 2023 to 2029. The market is mainly driven by the significant applications of Xerostomia (Dry Mouth Disease) Therapeutics in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Xerostomia (Dry Mouth Disease) Therapeutics market. Artificial Saliva, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Salivary Stimulants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Xerostomia (Dry Mouth Disease) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Xerostomia (Dry Mouth Disease) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Xerostomia (Dry Mouth Disease) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Xerostomia (Dry Mouth Disease) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Xerostomia (Dry Mouth Disease) Therapeutics covered in this report include Acacia Pharma, Church & Dwight, GlaxoSmithKline, Hikma Pharmaceuticals, Lupin, OraCoat, Parnell Pharmaceuticals, Pendopharm and Pfizer, etc.
The global Xerostomia (Dry Mouth Disease) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Global Xerostomia (Dry Mouth Disease) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Xerostomia (Dry Mouth Disease) Therapeutics market, Segment by Type:
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Global Xerostomia (Dry Mouth Disease) Therapeutics market, by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Xerostomia (Dry Mouth Disease) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
The global Xerostomia (Dry Mouth Disease) Therapeutics market size is expected to reach US$ 673.7 million by 2029, growing at a CAGR of 2.4% from 2023 to 2029. The market is mainly driven by the significant applications of Xerostomia (Dry Mouth Disease) Therapeutics in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Xerostomia (Dry Mouth Disease) Therapeutics market. Artificial Saliva, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Salivary Stimulants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Xerostomia (Dry Mouth Disease) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Xerostomia (Dry Mouth Disease) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Xerostomia (Dry Mouth Disease) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Xerostomia (Dry Mouth Disease) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Xerostomia (Dry Mouth Disease) Therapeutics covered in this report include Acacia Pharma, Church & Dwight, GlaxoSmithKline, Hikma Pharmaceuticals, Lupin, OraCoat, Parnell Pharmaceuticals, Pendopharm and Pfizer, etc.
The global Xerostomia (Dry Mouth Disease) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen
Global Xerostomia (Dry Mouth Disease) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Xerostomia (Dry Mouth Disease) Therapeutics market, Segment by Type:
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Global Xerostomia (Dry Mouth Disease) Therapeutics market, by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Xerostomia (Dry Mouth Disease) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Xerostomia (Dry Mouth Disease) Therapeutics
1.1 Xerostomia (Dry Mouth Disease) Therapeutics Market Overview
1.1.1 Xerostomia (Dry Mouth Disease) Therapeutics Product Scope
1.1.2 Xerostomia (Dry Mouth Disease) Therapeutics Market Status and Outlook
1.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2018-2029)
1.4 Global Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
1.6.1 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
1.6.2 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size (2018-2029)
2 Xerostomia (Dry Mouth Disease) Therapeutics Market by Type
2.1 Introduction
2.1.1 Artificial Saliva
2.1.2 Salivary Stimulants
2.1.3 Saliva Substitutes
2.1.4 Drugs
2.1.5 Salivary Pens
2.1.6 Others
2.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Xerostomia (Dry Mouth Disease) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Retail Pharmacies
3.1.2 Hospital Pharmacies
3.1.3 Online Pharmacies
3.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Xerostomia (Dry Mouth Disease) Therapeutics Competition Analysis by Players
4.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Xerostomia (Dry Mouth Disease) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Xerostomia (Dry Mouth Disease) Therapeutics Market
4.4 Global Top Players Xerostomia (Dry Mouth Disease) Therapeutics Headquarters and Area Served
4.5 Key Players Xerostomia (Dry Mouth Disease) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Xerostomia (Dry Mouth Disease) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Acacia Pharma
5.1.1 Acacia Pharma Profile
5.1.2 Acacia Pharma Main Business
5.1.3 Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.1.4 Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Acacia Pharma Recent Developments
5.2 Church & Dwight
5.2.1 Church & Dwight Profile
5.2.2 Church & Dwight Main Business
5.2.3 Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.2.4 Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Church & Dwight Recent Developments
5.3 GlaxoSmithKline
5.3.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.3.4 GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Hikma Pharmaceuticals Recent Developments
5.4 Hikma Pharmaceuticals
5.4.1 Hikma Pharmaceuticals Profile
5.4.2 Hikma Pharmaceuticals Main Business
5.4.3 Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.4.4 Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Hikma Pharmaceuticals Recent Developments
5.5 Lupin
5.5.1 Lupin Profile
5.5.2 Lupin Main Business
5.5.3 Lupin Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.5.4 Lupin Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Lupin Recent Developments
5.6 OraCoat
5.6.1 OraCoat Profile
5.6.2 OraCoat Main Business
5.6.3 OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.6.4 OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 OraCoat Recent Developments
5.7 Parnell Pharmaceuticals
5.7.1 Parnell Pharmaceuticals Profile
5.7.2 Parnell Pharmaceuticals Main Business
5.7.3 Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.7.4 Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Parnell Pharmaceuticals Recent Developments
5.8 Pendopharm
5.8.1 Pendopharm Profile
5.8.2 Pendopharm Main Business
5.8.3 Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.8.4 Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Pendopharm Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.9.4 Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Sun Pharmaceutical Industries
5.10.1 Sun Pharmaceutical Industries Profile
5.10.2 Sun Pharmaceutical Industries Main Business
5.10.3 Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.10.4 Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Sun Pharmaceutical Industries Recent Developments
5.11 Synedgen
5.11.1 Synedgen Profile
5.11.2 Synedgen Main Business
5.11.3 Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Products, Services and Solutions
5.11.4 Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Synedgen Recent Developments
6 North America
6.1 North America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Xerostomia (Dry Mouth Disease) Therapeutics Market Dynamics
11.1 Xerostomia (Dry Mouth Disease) Therapeutics Industry Trends
11.2 Xerostomia (Dry Mouth Disease) Therapeutics Market Drivers
11.3 Xerostomia (Dry Mouth Disease) Therapeutics Market Challenges
11.4 Xerostomia (Dry Mouth Disease) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
